Loading...
Publication
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.18 MB | Adobe PDF |
Advisor(s)
Abstract(s)
"Objective: To develop a novel and potent fusion inhibitor of HIV infection based on a rational strategy for synthetic antibody library construction.
Design: The reduced molecular weight of single-domain antibodies (sdAbs) allows targeting of cryptic epitopes, the most conserved and critical ones in the context of HIV entry. Heavy-chain sdAbs from camelids are particularly suited for this type of epitope recognition because of the presence of long and flexible antigen-binding regions [complementary-determining regions (CDRs)]."
Description
This is a non-final version of an article published in final form in AIDS. 2016 Jul 17;30(11):1691-701.
Keywords
HIV fusion inhibitor HR1 Single-domain antibody Synthetic library Variable light-chain
Citation
AIDS. 2016 Jul 17;30(11):1691-701. doi: 10.1097/QAD.0000000000001108.
Publisher
Wolters Kluwer